%0 Journal Article
%T Evaluation of Plasma Amyloid Peptides Aβ1-40 and Aβ1-42 as Diagnostic Biomarker of Alzheimer's Disease, its Association with Different Grades of Clinical Severity and 18F-Fluorodeoxyglucose Positron Emission Tomography Z score in the Indian Population: A Case-Control Study.
%A Soni H
%A Goyal MK
%A Sarma P
%A Singh H
%A Modi M
%A Sharma A
%A Mohanty M
%A Vishnu VY
%A Kumar A
%A Mittal BR
%A Medhi B
%J Indian J Nucl Med
%V 36
%N 4
%D Oct-Dec 2021
%M 35125757
暂无%R 10.4103/ijnm.ijnm_50_21
%X <B>BACKGROUND: </B>We estimated plasma amyloid-peptides levels (Aβ1-42 and Aβ1-40) as diagnostic biomarker of Alzheimer's disease (AD) and evaluated its association with clinical severity and 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) Z score of the different brain regions in the Indian population.<BR><B>METHODS: </B>A case-control study was conducted. Diagnostic and statistical manual-IV, Dubois, and NIA-AA criteria were used for the diagnosis of AD. The plasma Aβ1-42 and Aβ1-40 concentration and 18F-FDG PET Z score were estimated for different brain regions.<BR><B>RESULTS: </B>Forty-seven cognitive impairment patients (AD = 29, mild cognitive impairment = 18) and 33 age-matched controls were enrolled. Plasma Aβ1-42 level was significantly higher in the AD group compared to controls (P = 0.046) and a cut-off >5.7 ng/mL has a specificity of 96.9%, sensitivity of 27.6%, positive predictive value 88.9%, and negative predictive value 60.4% for differentiating AD patients from controls. Significant correlation was seen between Aβ1-40/Aβ1-42 ratio and 18F-FDG PET Z score in the bilateral-parietal, temporal, frontal-association area, and posterior-cingulate areas.<BR><B>CONCLUSIONS: </B>As a diagnostic biomarker of AD, plasma Aβ1-42 level showed good specificity but low sensitivity in the Indian population.